ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 1941 • ACR Convergence 2021

    The Risk of Venous Thromboembolic Events in Patients with RA Aged ≥ 50 Years with ≥ 1 Cardiovascular Risk Factor: Results from a Phase 3b/4 Randomized Safety Study of Tofacitinib vs TNF Inhibitors

    Christina Charles-Schoeman1, Roy Fleischmann2, Eduardo Mysler3, Maria Greenwald4, Cunshan Wang5, All-shine Chen5, Carol A Connell5, John C Woolcott6, Sujatha Menon5, Yan Chen7, Kristen Lee7 and Zoltan Szekanecz8, 1Department of Medicine, University of California, Los Angeles, Los Angeles, CA, 2Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, 3Organización Médica de Investigación, Buenos Aires, Argentina, 4Desert Medical Advances, Palm Desert, CA, 5Pfizer Inc, Groton, CT, 6Pfizer Inc, Collegeville, PA, 7Pfizer Inc, New York, NY, 8Division of Rheumatology, University of Debrecen, Faculty of Medicine, Debrecen, Hungary

    Background/Purpose: ORAL Surveillance (NCT02092467) was a randomized, open-label, non-inferiority, Phase 3b/4 study that assessed the relative risk of major adverse cardiovascular (CV) events (MACE) and…
  • Abstract Number: 1936 • ACR Convergence 2021

    A Neutrophil Degranulation Signature Identifies Proliferative Lupus Nephritis

    Andrea Fava1, Jessica Li1, Daniel Goldman2, Brendan Antiochos1, Jose Monroy-Trujillo1, Derek Fine1, Mohamed G. Atta1, Jill Buyon3, Joel Guthridge4, Judith James4, Michelle Petri2 and Accelerating Medicines Partership (AMP) RA/SLE Network5, 1Johns Hopkins University, Baltimore, MD, 2Johns Hopkins University School of Medicine, Baltimore, MD, 3NYU School of Medicine, New York, NY, 4Oklahoma Medical Research Foundation, Oklahoma City, OK, 5Brigham and Women's Hospital, Everett, MA

    Background/Purpose: The identification of intrarenal pathological processes is key to develop better diagnostic and treatment strategies in lupus nephritis (LN). But the direct comprehensive study…
  • Abstract Number: 1932 • ACR Convergence 2021

    Identifying Clusters of Longitudinal Autoantibody Profiles Associated with Systemic Lupus Erythematosus Disease Outcomes

    May Choi1, Irene Chen2, Ann Clarke3, Marvin Fritzler3, Katherine Buhler3, Murray Urowitz4, John Hanly5, Caroline Gordon6, Yvan St.Pierre7, Sang-Cheol Bae8, Juanita Romero-Diaz9, Francisco Sanchez-Guerrero10, Sasha Bernatsky11, Daniel Wallace12, David Isenberg13, Anisur Rahman14, Joan Merrill15, Paul R Fortin16, Dafna Gladman17, Ian N. Bruce18, Michelle Petri19, Ellen Ginzler20, Mary Anne Dooley21, Rosalind Ramsey-Goldman22, Susan Manzi23, Andreas Jnsen24, Graciela Alarcn25, Ronald van Vollenhoven26, Cynthia Aranow27, Meggan Mackay27, Guillermo Ruiz-Irastorza28, S Sam Lim29, Murat Inanc30, Kenneth Kalunian31, Sren Jacobsen32, Christine Peschken33, Diane Kamen34, Anca Askanase35, David Sontag2 and Karen Costenbader36, 1Brigham and Women's Hospital | University of Calgary, Calgary, AB, Canada, 2Massachusetts Institute of Technology, Cambridge, MA, 3University of Calgary, Calgary, AB, Canada, 4Center for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, University of Toronto, Lupus Clinic, Toronto, ON, Canada, 5Dalhousie University, Halifax, NS, Canada, 6Rheumatology Research Group, Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom, 7Research Institute of the McGill University Health Centre, Montréal, QC, Canada, 8Hanyang University Medical Center, Seoul, Republic of Korea, 9Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Ciudad de México, Federal District, Mexico, 10University Health Network/Sinai Health system, Toronto, ON, Canada, 11McGill University, Montréal, QC, Canada, 12Cedars-Sinai, Los Angeles, CA, 13Centre for Rheumatology, University College London, London, United Kingdom, 14University College London, London, United Kingdom, 15Oklahoma Medical Research Foundation, Oklahoma City, OK, 16CHU de Quebec - Universite Laval, Québec City, QC, Canada, 17Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, 18University of Manchester, Manchester, United Kingdom, 19Johns Hopkins University School of Medicine, Baltimore, MD, 20SUNY Downstate Health Sciences University, Brooklyn, NY, 21Raleigh Neurology Associates, Chapel Hill, NC, 22Northwestern University, Chicago, IL, 23Allegheny Health Network, Wexford, PA, 24Lund University, Lund, Sweden, 25University of Alabama at Birmingham, Birmingham, AL, 26Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Center, Amsterdam Rheumatology Center, Amsterdam, Netherlands, 27Feinstein Institutes for Medical Research, Manhasset, NY, 28Hospital Universitario Cruces, University of the Basque Country, Bizkaia, Spain, 29Department of Medicine, Division of Rheumatology, Emory University School of Medicine, Atlanta, GA, 30Istanbul University Faculty of Medicine, Istanbul, Turkey, 31UC San Diego, La Jolla, CA, 32Copenhagen Lupus and Vasculitis Clinic, Centre for Rheumatology and Spine Diseases, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark, 33University of Manitoba, Winnipeg, MB, Canada, 34Medical University of South Carolina, Charleston, SC, 35Columbia University Medical Center, New York, NY, 36Brigham and Women's Hospital, Belmont, MA

    Background/Purpose: Prior studies of SLE clusters based on autoantibodies have utilized cross-sectional data from single centers. We applied clustering techniques to longitudinal and comprehensive autoantibody…
  • Abstract Number: PP01 • ACR Convergence 2021

    Unicycling for a Cure: My UNIque Physical Activity Intervention for Rheumatoid Arthritis During the COVID19 Pandemic

    Dana Guglielmo, San Diego, CA

    Background/Purpose: I was diagnosed with rheumatoid arthritis at age 17. In my 20s, I joined Racing For A Cure of the Arthritis National Research Foundation,…
  • Abstract Number: PP02 • ACR Convergence 2021

    Leveraging Digital Health Tracking to Improve Arthritis Management

    Katie Roberts, Annapolis, MD

    Background/Purpose: I was diagnosed with psoriasis when I was age 10 in 1986. At that time, my treatment plan consisted of regular application of Eucerin…
  • Abstract Number: PP05 • ACR Convergence 2021

    Fighting Health-Related Misinformation Using Social Media / How Creating an Online Group for Patients with Relapsing Polychondritis — and Moderating It with Health Professionals — Helps Spread Reliable and Empowering Information

    Michael Linn1, Spenser Mestel2 and Susie Ratledge3, 1Relapsing Polychondritis Foundation, New York, NY, 2New York, NY, 3Relapsing Polychondritis: Secular Science and Support group, Chattanooga, TN

    Background/Purpose: Before I became ill in 2017, I was a registered nurse with a degree in health science who'd often educate patients about how they…
  • Abstract Number: PP04 • ACR Convergence 2021

    Dual Roles: Thriving with SLE as a Medical Student

    Chieh Lo1 and Song-Chou Hsieh2, 1School of Medicine, I-Shou Univerity, Kaohsiung, Taiwan (Republic of China), 2Division of Immunology, Allergy and Rheumatology, Department of Medicine, National Taiwan University Hospital, Taipei, Taiwan (Republic of China)

    Background/Purpose: A few days after my 18th birthday, I walked into a rheumatology clinic for the first time. I had ulcers in my mouth, felt…
  • Abstract Number: PP06 • ACR Convergence 2021

    Collaborative Advocacy Helps Me and Other Patients With Relapsing Polychondritis (“RP”’) /  My life improved by helping the RP Foundation and Race for RP facilitate awareness, education, and research to improve the quality of life for patients with RP and advance a cure for this disease.

    Michael Linn1 and Dan Smith2, 1Relapsing Polychondritis Foundation, New York, NY, 2Relapsing Polychondritis Foundation, Canton, MI

    Background/Purpose: In March 2020, I was diagnosed as having relapsing polychondritis ("RP"), an understudied, underdiagnosed, and undertreated debilitating autoimmune disease that can be fatal if…
  • Abstract Number: PP03 • ACR Convergence 2021

    Navigating Maintenance of a Rare Autoimmune Rheumatic Disease in the Context of the COVID-19 Pandemic

    Ida Hakkarinen, Greenbelt, MD

    Background/Purpose: On March 13th, 2020, the President of the United States issued a proclamation declaring that the outbreak of coronavirus disease 2019 (COVID-19) was a…
  • Abstract Number: 1930 • ACR Convergence 2021

    Single-Cell Genomics Reveals a Shared Monocyte Interferon Program in a Subset of Patients with Systemic Juvenile Idiopathic Arthritis, Macrophage Activation Syndrome and Lung Disease

    Emely Verweyen1, Kairavee Thakkar2, Kashish Chetal2, Sanjeev Dhakal3, Alexei Grom2, Nathan Salomonis2 and Grant Schulert2, 1Cincinnati Children's Hospital, Cincinnati, OH, 2Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 3Cincinnati Children hospital, Cincinnati, OH

    Background/Purpose: Systemic juvenile idiopathic arthritis (SJIA) is a clinically heterogenous disease and can be complicated by macrophage activation syndrome (MAS) and lung disease (LD) thought…
  • Abstract Number: PP10 • ACR Convergence 2021

    Discovering ‘I’ Through Interaction with Support Group Members: A Place of Empathy That Transcends the Limitations of Words

    Noriko Okochi1, Eiji Oishi2 and Mika Ishiguro1, 1Rheumatic Disease and Vasculitis Support Network Japan, Tokyo, Japan, 2Rheumatic Disease and Vasculitis Support Network Japan, Yamaguchi, Japan

    Background/Purpose: Since 5-year-old, I have had unexplained symptoms. At the age of 13, my whole body became inflamed. The pain was so intense that I…
  • Abstract Number: PP12 • ACR Convergence 2021

    Fighting for the Care We Deserve: My Experience as a Latina Patient-Researcher During the COVID-19 Pandemic

    Guadalupe Torres1, Courtney Wells2 and Kristine Carandang3, 1, 2University of Wisconsin-River Falls, School of Social Work, St. Paul, MN, 3Global Healthy Living Foundation, CreakyJoints, San Diego, CA

    Background/Purpose: I am a 23-year-old first generation Latina with rheumatoid arthritis (RA). Despite being disproportionately affected by rheumatic conditions, the perspectives of Latinx remain poorly…
  • Abstract Number: PP08 • ACR Convergence 2021

    Should I Get the COVID-19 Vaccine With My RA? Using Evidence-Based Resources for Decision-Making

    Aberdeen Allen, Colgate Palmolive, Parlin, NJ

    Background/Purpose: Patients with autoimmune rheumatic diseases have concerns about getting the COVID-19 vaccine. As vaccines began to receive emergency use authorization, individuals with conditions like…
  • Abstract Number: 1933 • ACR Convergence 2021

    Association Between Race/Ethnicity and COVID-19 Outcomes in Systemic Lupus Erythematosus (SLE) in United States Patients: Data from the COVID-19 Global Rheumatology Alliance

    Manuel Ugarte-Gil1, Graciela Alarcn2, Andrea Seet3, Zara Izadi3, Ali Duarte-Garcia4, Emily Gilbert5, Maria Valenzuela-Almada6, Leanna Wise7, Jeffrey Sparks8, Tiffany Hsu9, Kristin D'Silva10, Naomi Patel10, Emily Sirotich11, Jean Liew12, Jonathan Hausmann13, Paul Sufka14, Rebecca Grainger15, Suleman Bhana16, Wendy Costello17, Zachary Wallace18, Lindsay Jacobsohn19, Anja Strangfeld20, Elsa Frazão Mateus21, Kimme Hyrich22, Laure Gossec23, Loreto Carmona24, Saskia Lawson-Tovey22, Lianne Kearsley-Fleet25, Martin Schaefer26, Pedro Machado27, Philip Robinson28, Milena Gianfrancesco3 and Jinoos Yazdany3, 1Hospital Guillermo Almenara Irigoyen, Essalud/Universidad Científica del Sur, Lima, Peru, 2University of Alabama at Birmingham, Birmingham, AL, 3University of California San Francisco, San Francisco, CA, 4Mayo Clinic, Rochester, MN, 5Mayo Clinic, Jacksonville, FL, 6Division of Rheumatology, Mayo Clinic, Rochester, MN, 7LAC+USC/Keck Medicine of USC, Pasadena, CA, 8Brigham and Women's Hospital, Boston, MA, 9Brigham and Women's Hospital, Jamaica Plain, MA, 10Massachusetts General Hospital, Boston, MA, 11McMaster University, Hamilton, ON, Canada, 12Boston University, Boston, MA, 13Boston Children's Hospital / Beth Israel Deaconess Medical Center, Cambridge, MA, 14HealthPartners, Eagan, MN, 15University of Otago, Wellington, New Zealand, 16Crystal Run Health, Montvale, NJ, 17Irish Children's Arthritis Network, Bansha, Ireland, 18Massachusetts General Hospital, Newton, MA, 19University of California San Francisco, Antioch, CA, 20Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, 21Liga Portuguesa Contra as Doenças Reumáticas (LPCDR), Lisbon, Portugal, 22University of Manchester, Manchester, United Kingdom, 23Sorbonne Université; APHP, Rheumatology Department, Pitié-Salpêtrière Hospital, Paris, France, 24Instituto de Salud Musculoesqueltica (InMusc), Madrid, Spain, 25Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom, 26German Rheumatism Research Center, Berlin, Germany, 27Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, United Kingdom, 28Faculty of Medicine, The University of Queensland, Herston, Australia

    Background/Purpose: Hispanic and African American race/ethnicities have been associated with poor COVID-19 outcomes in the general population and in rheumatic disease patients within the COVID-19…
  • Abstract Number: 1836 • ACR Convergence 2021

    Outcomes Linked to Eligibility for Stem Cell Transplantation Trials in Diffuse Cutaneous Systemic Sclerosis

    Julia Spierings1, Svetlana Nihtyanova2, Emma Derrett-Smith3, Kristina Clark2, Jacob van Laar4, Voon Ong5 and Christopher Denton6, 1University Medical Center Utrecht, Utrecht, Netherlands, 2University College London, Royal Free Campus, London, United Kingdom, 3University College London Division of Medicine, London, United Kingdom, 4University Medical Centre Utrecht, Utrecht, Netherlands, 5University College London Medical School Royal Free Campus, London, United Kingdom, 6University College London Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, London, United Kingdom

    Background/Purpose: Autologous haematopoietic stem cell transplantation (SCT) has emerged as an effective treatment for patients with severe diffuse systemic sclerosis (dcSSc) based upon the results…
  • « Previous Page
  • 1
  • …
  • 647
  • 648
  • 649
  • 650
  • 651
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology